FLT3 and acute myeloid leukemia: Although the WHO lists FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) as a molecular genetic alteration significantly affecting the clinical outcome in patients with AML in specific cytogenetic subgroups [7], it does not group FLT3 mutations into a single category but rather divides them into many subgroups.